The Influence of MDR’s Article 117 in the Marketing of Combination Products

Regulatory Consulting

The European Union Medical Device Regulation’s (MDR) Article 117 brings improved patient safety measures with new implications for manufacturers, as they must fulfill a significant set of additional requirements.

Listen to the full episode on Veristat’s Advancing Revolutionary Therapies Podcast to learn more about the Article and its influence on the marketing of combination products.

Learning Points

  • What are Drug Device Combination (DDC) products
  • What is Article 117 of the MDR
  • The impact of Article 117 on Manufacturers

LISTEN TO PODCAST

 

Meet Veristat. Learn More.

1 min read

Chief Medical Officer Summit -CMO 360°

Apr 9, 2024  Veristat Events

Meet the Veristat team at Booth #3, April 17th and 18th in Boston

The Science-First CRO™ and Consultancy Ready to...

4 min read

Plenary Session Presentation: Putting Science First in Rare Disease Studies

Mar 22, 2024  Veristat Events

Don´t miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Boston, Thursday, April 25th at...